drugset / Trial / NCT05155709
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A study of siremadlin in combination with venetoclax plus azacitidine in adult participants with AML who are ineligible for chemotherapy. The primary purpose of this study was to assess whether siremadlin in combination with venetoclax plus azacitidine can enhance the clinical response in unfit AML participants without unacceptable levels of treatment-emergent toxicities.
Timeline
- Start
- 2022-05-17
- Primary completion
- 2024-04-17
- Completion
- 2024-04-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siremadlin | Small molecule | 20 mg | Oral |
| Background | Azacitidine | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Venetoclax | Small molecule | 400 mg | Oral |